Individuals who had an allergic reaction to a first dose of the Pfizer/BioNTech or Moderna mRNA COVID-19 vaccine tolerated a second dose safely, reported a retrospective, multicenter study.

Overall, 17% of the 189 individuals with initial allergic reactions had anaphylaxis. Other reactions to the first dose included erythema, dizziness, tingling, throat tightness, hives, and wheezing or shortness of breath. Among the 189 people with initial allergic reactions, researchers assessed 159 (84%) who took the second dose. All the individuals, including 19 people with first-dose anaphylaxis, tolerated the second dose. Thirty two people who took a second dose developed immediate and potentially allergic symptoms. About 20% of the individuals had symptoms with the second dose, but they were manageable and not anaphylactic, noted researchers. The findings are published in JAMA Internal Medicine… (Medscape)